Global Hemophilia Drugs Market 2016-2020; New Report Launched

DrugPipeline.net has announced the addition of “Global Hemophilia Drugs Market 2016-2020” research report to their website DrugPipeline.net


Bangalore, India -- (SBWIRE) -- 11/02/2016 -- Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

Report forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:
- Americas

Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios BioPharmaceutical
- Biogen
- BioMarin
- Catalyst Bioscience
- Chiesi Farmaceutici
- Dimension Therapeutics
- Emergent BioSolutions
- F. Hoffmann-La Roche
- Grifols, Kedrion Biopharma
- Octapharma
- rEVO Biologics
- OPKO Biologics
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
- UniQure Biopharma.

Market driver
- Focus on prophylactic treatment
- For a full, detailed list, view our report

Market challenge
- Low diagnosis rate
- For a full, detailed list, view our report

Market trend
- Increase in technological innovations
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 84 pages "Global Hemophilia Drugs Market 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Pipeline portfolio, Market landscape, Market segmentation by type of disease, Market segmentation by type of therapy, Market segmentation by type of disease management, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-hemophilia-drugs-market-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.